← All trials
NCT05227846
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 22, 2022
- Primary completion
- Dec 30, 2022
- Completion date
- Mar 1, 2025
- First posted
- Feb 7, 2022
- Last posted
- Jul 29, 2022
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Zhongyuan Union Stem Cell Bio-engineering CorporationCollaborator
- People's Liberation Army of ChinaReponsible party - principal investigator
- People's Liberation Army of ChinaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.